Morgan Stanley has kept an equal-weight rating on the stock with a target price of ₹1,375.
Investors are particularly concerned about the company's recent move into the healthcare sector and its potential impact on the asset-light nature of the business. It is premature to assess the potential financial impact. Investor sentiment will be influenced by the magnitude of the capital outlay—whether it is one-time or recurring—as well as whether it involves a solo venture or multiple partners, and what the company envisions as benefits to revenue and insurer-partner relationships.
Comments
Post a Comment